Eli Lilly, one of the world’s largest pharmaceutical companies, has launched a new platform in Australia designed to bypass traditional community pharmacies in dispensing certain medications, including its popular GLP-1 drug Mounjaro. The move aims to provide patients with more affordable and convenient access to the injectable medication, which is used to treat diabetes and support weight loss.
The platform, named LillyDirect, allows patients who have been prescribed eligible medicines to upload their prescriptions online. A network of licensed third-party pharmacies then competes to dispense and deliver the medications by mail. Eli Lilly Australia and New Zealand general manager Manny Simons said the initiative is a response to patient and doctor demands for better access and affordability amid challenges in securing federal government reimbursement for these medicines.
“Tirzepatide, sold under the brand Mounjaro, has experienced significant demand, especially in Australia’s private market, where sales of medicines outside the Pharmaceutical Benefits Scheme (PBS) are at record levels,” Simons explained. Sales for Eli Lilly’s weight-loss drugs contributed to a 48% increase in global revenue in the second quarter of 2026.
The company emphasized that the new service operates within established medicine supply frameworks and only on prescriptions independently issued by doctors. While Eli Lilly is restricted by competition laws from disclosing exact price reductions under LillyDirect, industry analysis estimates that patients might save modest amounts on lower doses and up to approximately A$50 on higher doses compared to purchases through standard pharmacies.
Despite no official pharmacy margin regulation in Australia, recent assessments suggest dispensing fees could represent up to 20% of the medication cost, though competition for these high-demand drugs might reduce fees somewhat. Simons acknowledged that while the savings will not match PBS-level subsidies, the platform is a practical step toward improved affordability, especially given the current impasse over government reimbursement for Mounjaro.
Lilly’s decision to exclude Mounjaro from PBS listing for diabetes followed a pricing dispute with the federal Health Department, leaving many patients to either pay privately or use alternative subsidized GLP-1 drugs such as Ozempic, which are not effective for all patients.
However, the shift away from face-to-face dispensing has drawn criticism from healthcare professionals. Fred Betros, a general surgeon and NSW branch president of the Australian Medical Association who previously trained as a pharmacist, expressed concerns that LillyDirect could fragment care by separating patients from pharmacists and prescribers. He emphasized the importance of in-person guidance, particularly given the challenges some may face in using injectable pens correctly.
The Royal Australian College of General Practitioners also does not endorse the platform. College president Michael Wright highlighted that medications like Mounjaro require careful monitoring due to their potency and potential side effects. Conversely, GP Paige Lanyon-Roberts, who specializes in metabolic health, contended that the responsibility for patient education remains firmly with the prescribing doctor, dismissing worries about fragmented care.
As public healthcare services for severe obesity remain under-resourced and many patients face difficulty accessing subsidized pharmacotherapies, Eli Lilly’s LillyDirect initiative represents a significant shift in the Australian medicines distribution system, balancing improved access with ongoing debates about patient safety and healthcare integration.